252 related articles for article (PubMed ID: 28747060)
1. Treatment persistence during therapeutic sequences with adalimumab and infliximab in the treatment of Crohn's disease.
Taxonera C; Robledo P; Rodríguez A
Rev Esp Enferm Dig; 2017 Oct; 109(10):690-693. PubMed ID: 28747060
[TBL] [Abstract][Full Text] [Related]
2. Fourteen-Year Anti-TNF Therapy in Crohn's Disease Patients: Clinical Characteristics and Predictive Factors.
Osamura A; Suzuki Y
Dig Dis Sci; 2018 Jan; 63(1):204-208. PubMed ID: 29209921
[TBL] [Abstract][Full Text] [Related]
3. Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation.
Viazis N; Koukouratos T; Anastasiou J; Giakoumis M; Triantos C; Tsolias C; Theocharis G; Karamanolis DG
Eur J Gastroenterol Hepatol; 2015 Apr; 27(4):436-41. PubMed ID: 25874518
[TBL] [Abstract][Full Text] [Related]
4. SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN'S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB.
Bau M; Zacharias P; Ribeiro DA; Boaron L; Steckert Filho A; Kotze PG
Arq Gastroenterol; 2017 Dec; 54(4):328-332. PubMed ID: 28954043
[TBL] [Abstract][Full Text] [Related]
5. Experience With Anti-TNF-α Biologic Agents in Succession in Patients With Crohn's Disease: A Retrospective Analysis of a Single Center.
Ferges W; Rampertab SD; Shafqet M; Salimi Q; You G; Yousefzadeh E; Cheng JQ; Das KM
J Clin Gastroenterol; 2016 Apr; 50(4):326-30. PubMed ID: 25984976
[TBL] [Abstract][Full Text] [Related]
6. Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes: A Retrospective Cohort Study.
Ma C; Beilman CL; Huang VW; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
Inflamm Bowel Dis; 2016 Apr; 22(4):870-9. PubMed ID: 26818419
[TBL] [Abstract][Full Text] [Related]
7. Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.
Rencz F; Gulácsi L; Péntek M; Gecse KB; Dignass A; Halfvarson J; Gomollón F; Baji P; Peyrin-Biroulet L; Lakatos PL; Brodszky V
Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):597-606. PubMed ID: 28434387
[TBL] [Abstract][Full Text] [Related]
8. Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study.
Doecke JD; Hartnell F; Bampton P; Bell S; Mahy G; Grover Z; Lewindon P; Jones LV; Sewell K; Krishnaprasad K; Prosser R; Marr D; Fischer J; R Thomas G; Tehan JV; Ding NS; Cooke SE; Moss K; Sechi A; De Cruz P; Grafton R; Connor SJ; Lawrance IC; Gearry RB; Andrews JM; Radford-Smith GL;
Aliment Pharmacol Ther; 2017 Feb; 45(4):542-552. PubMed ID: 27995633
[TBL] [Abstract][Full Text] [Related]
9. Effect of tumor necrosis factor-α antagonists on oxidative stress in patients with Crohn's disease.
Yamamoto K; Chiba T; Matsumoto T
World J Gastroenterol; 2015 Sep; 21(35):10208-14. PubMed ID: 26401086
[TBL] [Abstract][Full Text] [Related]
10. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.
Gagniere C; Beaugerie L; Pariente B; Seksik P; Amiot A; Abitbol V; Allez M; Cosnes J; Sokol H
J Crohns Colitis; 2015 Apr; 9(4):349-55. PubMed ID: 25547977
[TBL] [Abstract][Full Text] [Related]
11. Early Initiation of Tumor Necrosis Factor Antagonist-Based Therapy for Patients With Crohn's Disease Reduces Costs Compared With Late Initiation.
Beilman CL; Kirwin E; Ma C; McCabe C; Fedorak RN; Halloran B
Clin Gastroenterol Hepatol; 2019 Jul; 17(8):1515-1524.e4. PubMed ID: 30056180
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.
Benmassaoud A; Al-Taweel T; Sasson MS; Moza D; Strohl M; Kopylov U; Paradis-Surprenant L; Almaimani M; Bitton A; Afif W; Lakatos PL; Bessissow T
Dig Dis Sci; 2018 May; 63(5):1302-1310. PubMed ID: 29243105
[TBL] [Abstract][Full Text] [Related]
13. Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease.
Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1120-1129.e6. PubMed ID: 27058635
[TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers.
Stoppino LP; Della Valle N; Rizzi S; Cleopazzo E; Centola A; Iamele D; Bristogiannis C; Stoppino G; Vinci R; Macarini L
BMC Med Imaging; 2016 May; 16(1):37. PubMed ID: 27149857
[TBL] [Abstract][Full Text] [Related]
15. Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease.
Weizman AV; Sharma R; Afzal NM; Xu W; Walsh S; Stempak JM; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
Dig Dis Sci; 2018 Sep; 63(9):2430-2438. PubMed ID: 29736839
[TBL] [Abstract][Full Text] [Related]
16. A Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn's Disease Treated with Adalimumab or Infliximab.
Yokoyama K; Yamazaki K; Katafuchi M; Ferchichi S
Adv Ther; 2016 Nov; 33(11):1947-1963. PubMed ID: 27664107
[TBL] [Abstract][Full Text] [Related]
17. Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience.
Peyrin-Biroulet L; Salleron J; Filippi J; Reenaers C; Antunes O; Filipe V; Louis E; Hébuterne X; Roblin X
J Crohns Colitis; 2016 May; 10(5):516-24. PubMed ID: 26802084
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first-line biologics.
Inokuchi T; Takahashi S; Hiraoka S; Toyokawa T; Takagi S; Takemoto K; Miyaike J; Fujimoto T; Higashi R; Morito Y; Nawa T; Suzuki S; Nishimura M; Inoue M; Kato J; Okada H
J Gastroenterol Hepatol; 2019 Aug; 34(8):1329-1336. PubMed ID: 30724387
[TBL] [Abstract][Full Text] [Related]
19. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease.
Lindsay JO; Armuzzi A; Gisbert JP; Bokemeyer B; Peyrin-Biroulet L; Nguyen GC; Smyth M; Patel H
Dig Liver Dis; 2017 Oct; 49(10):1086-1091. PubMed ID: 28826571
[TBL] [Abstract][Full Text] [Related]
20. Lymphomatoid Papulosis Type B in a Patient with Crohn's Disease Treated with TNF-Alpha Inhibitors Infliximab and Adalimumab.
Medvecz M; Kiss N; Hársing J; Kuroli E; Hegede G; Csomor J; Kárpáti S; Marschalkó M
Acta Dermatovenerol Croat; 2019 Sep; 27(3):202-204. PubMed ID: 31542070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
